Jieduquyuziyin Prescription alleviates hepatic gluconeogenesis via PI3K/Akt/PGC-1α pathway in glucocorticoid-induced MRL/lpr mice

Ji, Lina; Wu, Shan; Fu, Danqing; Fang, Sijia; Xie, Guanqun; Fan, Yongsheng; Bao, Jie

doi:10.1016/j.jep.2021.114815

Cited by 7 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, using these formulae for a long period would consume healthy Qi. Jieduquyuziyin prescription, which contains both herbs from KF and BF formulae, has been shown to ameliorate SLE in MRL/lpr mice by inhibiting the expression of the IRAK1-NF-κB and PI3K/Akt/PGC-1α signaling pathways ( Ji et al, 2020 ; Ji et al, 2022 ). Therefore, the underlying mechanisms by which TCM therapies may reduce the risk of pneumonia in patients with SLE need further investigations in the future.…”

Section: Discussionmentioning

confidence: 99%

Traditional Chinese medicine use is associated with lower risk of pneumonia in patients with systemic lupus erythematosus: a population-based retrospective cohort study

Wang

Yang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objectives: To investigate the association between traditional Chinese medicine (TCM) therapy and the risk of pneumonia in patients with systemic lupus erythematosus (SLE).Methods: This population-based control study analyzed the data retrieved from the National Health Insurance Research database in Taiwan. From a cohort of 2 million records of the 2000–2018 period, 9,714 newly diagnosed patients with SLE were initially included. 532 patients with pneumonia and 532 patients without pneumonia were matched 1:1 based on age, sex, and year of SLE diagnosis using propensity score matching. The use of TCM therapy was considered from the SLE diagnosis date to the index date and the cumulative days of TCM therapy were used to calculate the dose effect. Conditional logistic regression was used to investigate the risk of pneumonia infection. Furthermore, to explore the severity of pneumonia in SLE, sensitivity analyses were performed after stratification using the parameters of emergency room visit, admission time, and antibiotic use.Results: TCM therapy for >60 days could significantly reduce the risk of pneumonia in patients with SLE (95% CI = 0.46–0.91; p = 0.012). Stratified analysis showed that TCM use also reduced the risk of pneumonia in younger and female patients with SLE by 34% and 35%, respectively. TCM for >60 days significantly reduced the risk of pneumonia in the follow-up periods of >2, >3, >7, and >8 years. In addition, the exposure of TCM for >60 days reduced the risk of pneumonia in patients with SLE who were treated with antibiotics for moderate or severe pneumonia. Finally, the study found that using formulae to tonify the kidney for more than 90 days and formulae to activate blood circulation for less than 30 days could significantly reduce the risk of pneumonia infection in patients with SLE.Conclusion: TCM use is associated with a lower risk of pneumonia among patients with SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Traditional Chinese medicine use is associated with lower risk of pneumonia in patients with systemic lupus erythematosus: a population-based retrospective cohort study

Wang

Yang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The mice in the PF group were given 25, 50, and 75 mg/kg of PF dissolved in distilled water, respectively [ 25 ]. In the end, the spleen, kidney, urine, and blood were harvested after all the mice were euthanized with carbon dioxide [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

“…Te Jieduquyuziyin Prescription (JP), containing ten traditional Chinese herbs, is clinically used to treat SLE. Our previous research confrmed that JP could inhibit infammation, alleviate the side efects of clinical drugs, and reduce the incidence of infection [18]. Recent clinical studies have found that JP could reduce the side efects and enhance the efcacy of glucocorticoids (GC) in the treatment of SLE [19,20].…”

Section: Introductionmentioning

confidence: 99%

Paeoniflorin Inhibits LPS-Induced Activation of Splenic CD4+ T Lymphocytes and Relieves Pathological Symptoms in MRL/lpr Mice by Suppressing IRAK1 Signaling

Wang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

Interleukin-1receptor-associated kinase 1 (IRAK1) plays a critical role in systemic lupus erythematosus (SLE). It was reported that SLE was associated with an inflammatory response mediated by defective immune tolerance, including overproduction of autoantibodies, chronic inflammation, and organ damage. Previous reports stated paeoniflorin (PF) had an immunosuppressive effect. The purpose of this study was to determine the anti-inflammatory effect of PF in SLE and its underlying mechanisms. Followed by induced with lipopolysaccharide (LPS), the splenocytes and the isolated CD4+ T lymphocytes of MRL/lpr mice were divided into three groups: control group, LPS group, and LPS + PF group, respectively. MRL/MP mice were used as the control group (treated with distilled water). The MRL/lpr mice were randomly divided into three groups: the model group (treated with distilled water), the prednisone group, and the PF group. The MRL/lpr mice were treated with prednisone acetate (5 mg/kg) and PF (25, 50, and 75 mg/kg) for eight weeks. Subsequently, ELISA, qRT-PCR, western blotting, HE, and Masson staining were performed to detect various indicators. The results of Cell Counting Kit-8 (CCK-8) showed that 10 μg/mL of LPS had the optimum effect on cell viability, and 50 μmol/L of PF had no obvious cytotoxicity to LPS-treated cells. PF reduced the expression level of IRAK1-nuclearfactor-κB (NF-κB) and its downstream inflammatory cytokines in the splenocytes and CD4+ T lymphocytes of MRL/lpr mice stimulated by LPS, especially in the latter. The serum antibody contents in the PF group mice were reduced, and the kidney damage was also alleviated accordingly. Moreover, the IRAK1/inhibitor of the nuclear factor-κB kinase (IKK)/NF-κB inhibitor (IκB)/NF-κB pathways was found to be involved in the anti-inflammation effect of PF in the kidney and spleen. In conclusion, it is thought that PF may have the potential to be used as a therapeutic agent to reduce the inflammatory activity of SLE. Inhibition of the IRAK1-NF-κB pathway may help formulate novel therapeutic tactics for SLE.

show abstract

“…Dihydroartemisinin and prednisone work in synergy to mitigate SLE symptoms and re-establish Treg/Th17 balance [ 19 ]. In animal experiments, JQZF alleviates the symptoms of MRL/lpr mice [ 20 ]. A series of previous experimental animal studies confirmed that JQZF effectively inhibits disease activity in MRL/lpr mice by blocking the activation of the IRAK1-NF-κB signaling pathway [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

“…In animal experiments, JQZF alleviates the symptoms of MRL/lpr mice [ 20 ]. A series of previous experimental animal studies confirmed that JQZF effectively inhibits disease activity in MRL/lpr mice by blocking the activation of the IRAK1-NF-κB signaling pathway [ 20 ]. Further, it showcases anti-inflammatory and anti-fibrotic properties through the inhibition of NF-κB and α-SMA expression, contributing to LN prevention and treatment [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Investigating the therapeutic mechanism of Jiedu-Quyu-Ziyin Fang on systemic lupus erythematosus through the ERα-miRNA-TLR7 immune axis

Zhang,

Zhang

et al. 2024

Heliyon

View full text Add to dashboard Cite

Jieduquyuziyin Prescription alleviates hepatic gluconeogenesis via PI3K/Akt/PGC-1α pathway in glucocorticoid-induced MRL/lpr mice

Cited by 7 publications

References 56 publications

Traditional Chinese medicine use is associated with lower risk of pneumonia in patients with systemic lupus erythematosus: a population-based retrospective cohort study

Traditional Chinese medicine use is associated with lower risk of pneumonia in patients with systemic lupus erythematosus: a population-based retrospective cohort study

Paeoniflorin Inhibits LPS-Induced Activation of Splenic CD4+ T Lymphocytes and Relieves Pathological Symptoms in MRL/lpr Mice by Suppressing IRAK1 Signaling

Investigating the therapeutic mechanism of Jiedu-Quyu-Ziyin Fang on systemic lupus erythematosus through the ERα-miRNA-TLR7 immune axis

Contact Info

Product

Resources

About